Ianalumab
Monoclonal antibody
From Wikipedia, the free encyclopedia
Ianalumab (INN;[1] development code VAY736) is a monoclonal antibody that is being investigated for autoimmune hepatitis, multiple sclerosis, pemphigus vulgaris, rheumatoid arthritis, Sjogren's disease, Immune thrombocytopenic purpura and systemic lupus erythematosus.[2][3][4][5]
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Source | Human |
| Target | BAFF receptor |
| Clinical data | |
| Other names | VAY736 |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| DrugBank | |
| UNII | |
| KEGG | |
This drug is being developed by Novartis. In 2021 ianalumab was undergoing Phase II/III trials.[6][7] In June 2023 ianalumab was involved in 22 clinical trials, of which 3 were completed, 14 were ongoing, 1 was planned, and 4 were terminated.[8]
